207 reports of this reaction
1.5% of all TENOFOVIR DISOPROXIL FUMARATE TABLETS reports
#17 most reported adverse reaction
TREATMENT NONCOMPLIANCE is the #17 most commonly reported adverse reaction for TENOFOVIR DISOPROXIL FUMARATE TABLETS, manufactured by Chartwell RX, LLC.. There are 207 FDA adverse event reports linking TENOFOVIR DISOPROXIL FUMARATE TABLETS to TREATMENT NONCOMPLIANCE. This represents approximately 1.5% of all 14,129 adverse event reports for this drug.
Patients taking TENOFOVIR DISOPROXIL FUMARATE TABLETS who experience treatment noncompliance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT NONCOMPLIANCE is a less commonly reported adverse event for TENOFOVIR DISOPROXIL FUMARATE TABLETS, but still significant enough to appear in the safety profile.
In addition to treatment noncompliance, the following adverse reactions have been reported for TENOFOVIR DISOPROXIL FUMARATE TABLETS:
The following drugs have also been linked to treatment noncompliance in FDA adverse event reports:
TREATMENT NONCOMPLIANCE has been reported as an adverse event in 207 FDA reports for TENOFOVIR DISOPROXIL FUMARATE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT NONCOMPLIANCE accounts for approximately 1.5% of all adverse event reports for TENOFOVIR DISOPROXIL FUMARATE TABLETS, making it a notable side effect.
If you experience treatment noncompliance while taking TENOFOVIR DISOPROXIL FUMARATE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.